Clinical factors of development of squamous intraepithelial cervical lesions of high grade in patients with papillomavirus infection

Purpose of the study. To assess the chances of development of squamous intraepithelial cervical lesions of high degree (H‑SIL) in patients infected with human papillomavirus (HPV).

Patients and methods. 75 HPV positive patients. The main group — with a histological diagnosis of H‑SIL (n=50), the control group — with a histological diagnosis without H‑SIL (n=25). Liquid-based cytology, colposcopy, cervical excision; HPV test, diagnosis of sexually transmitted infections — PCR in real time; a comprehensive bacteriological study. Assessment tool interconnections — odds ratio, categorical data analysis — statistical packages STATISTICA 6.0 and SPSS 22 "Statistical Package for the Social Sciences".

Results. In the age group up to 30 years, the chances of H‑SIL development are 26 times higher, 30–40 years — 38 times higher compared to patients over 50 years (p<0.05). With a menstrual cycle of more than 35 days, the chances of H‑SIL development are 71 times greater than in patients with a normal menstrual cycle (p<0.05).Comparison of the chances of the presence of abnormal colposcopic patterns — the presence of significant lesions related to the II degree of colposcopic changes increases the chances of H‑SIL 8.4 times compared to the normal colposcopic pattern. The chances of development of H‑SIL in patients with colposcopy results of minor lesions (I degree), do not differ from those who have a normal colposcopic picture (p>0.05). The presence of chronic inflammatory diseases of the pelvic organs. Earlier treatment of cervical diseases by destruction reduces the risk of H‑SIL 0.08 times. The presence of chronic diseases of the pelvic organs increases the risk of H‑SIL 24 times (p<0.05).

Conclusion. The group at greatest risk of having H‑SIL -women 30–40 years, whose menstrual cycle is more than 35 days, with significant lesions according to the results of colposcopic examination, chronic diseases of the pelvic organs, which had not previously been carried out destruction of the cervix.

1. Kaprin AD, Ctarinsky VV, Petrova GV. The State of cancer care to the population of Russia in 2018. Moscow, 2019. Fig. 236 p. (In Russian).

2. Aksel EM. Incidence and Mortality from Malignant Tumors of the Female Reproductive System in Russia. Onkoginekologiya. 2015; (1): 6–15. (In Russian).

3. zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst. 2000 May 3; 92(9): 690–698. https://doi.org/10.1093/jnci/92.9.690

4. WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention. World Health Organization, 2013, 58 p.

5. Wentzensen N, Arbyn M, Berkhof J, Bower M, Canfell K, Einstein M, et al. Eurogin 2016 Roadmap: how HPV knowledge is changing screening practice. Int J Cancer. 2017 15; 140(10): 2192– 2000. https://doi.org/10.1002/ijc.30579

6. Bernard H.U. Taxonomy and phylogeny of papillomaviruses: an overview and recent developments. Infect Genet Evol. 2013 Aug; 18: 357–361. https://doi.org/10.1016/j.meegid.2013.03.011

7. Dimitriadi TA, Kholodnaya TO. Diagnosis and treatment of cervical pathology: a modern view of the problem News of higher educational institutions. North Caucasus region. Series: Natural Sciences. 2007; (5(141)): 95–100.

8. Donnikov AE, Markelov MI, Pestrikova TYu, Yurasova EA, Kotelnikova AV, Voroshilina ES, et al. Analysis of the prevalence and viral load of different human papillomavirus typesin the regions of the Russian Federation. Obstetrics and Gynecology. 2019; (4): 39–47. (In Russian). https://doi.org/10.18565/aig.2019.4.39–47

9. Salcedo M. P., Baker E. S., Schmeler K.M. Intraepithelial Neoplasia of the Lower Genital Tract (Cervix, Vagina, Vulva): Etiology, Screening, Diagnosis, Management. Comprehensive Gynecology. 2017; 28: 655–665. https://doi.org/10.1016/b978–0-323–06986–1.00028–7

10. Korolenkova LI. Human papillomavirus infection-associated markers of the occurrence and progression of cervical intraepithelial neoplasias: from research developments to clinical practice. Tumors of female reproductive system. 2010; (4): 64–70. (In Russian). https://doi.org/10.17650/1994–4098–2010–0-4–64–70

11. Anaman-Torgbor JA, King J, Correa-Velez I. Barriers and facilitators of cervical cancer screening practices among African immigrant women living in Brisbane, Australia. Eur J Oncol Nurs. 2017 Dec; 31: 22–29. https://doi.org/10.1016/j.ejon.2017.09.005

12. Moreno V, Bosch FX, Muñoz N, Meijer CJLM, Shah KV, Walboomers JMM, et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet. 2002 Mar 30; 359(9312): 1085–1092. https://doi.org/10.1016/S0140–6736(02)08150–3

13. Smith JS, Green J, Berrington de Gonzalez A, Appleby P, Peto J, Plummer M, et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet. 2003 Apr 5; 361(9364): 1159–1167. https://doi.org/10.1016/s0140–6736(03)12949–2